Synonyms: (S)-N-(1-(4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide; CAY10593; N-[(1S)-2-[4-(5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-naphthalenecarboxamide
Molecular Formula: C26H27ClN4O2
Molecular Weight: 462.97
Linear Structural Formula: C26H27ClN4O2
MDL Number: MFCD23160355
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: VU0155069 is a PLD1-selective catalytic site-targeting phospholipase D inhibitor (PLD1/2 IC50 = 46 nM/933 nM by cell-free enzymatic assays; substrate = di-palmitoyl-PLC) that selectively suppresses the cellular PLD activity in PMA-stimulated non-small-cell lung cancer (NSCLC) Calu-1 cells with predominant PLD1 activity over GFP-PLD2-overexpressing HEK293 cells (IC50 = 11 nM and 1.8 muM, respectively). Note: VU0155069 is reported to impair P2X7-induced pore formation in human RPMI 8226 B cells lacking PLD1 expression.